Prognostic factors and complication rates for double-filtration plasmapheresis in patients with Guillain-Barré syndrome.

Guillain-Barré syndrome (GBS) is an acute immune-mediated demyelinating polyradiculoneuropathy that could lead to disabilities if not properly treated. There are only limited data on the prognostic factors and complications when using double-filtration plasmapheresis in these patients. We reviewed the medical records of 60 GBS patients who underwent double-filtration plasmapheresis as the first-line therapy at a tertiary care teaching hospital. The severity of disease was evaluated at different time points using disability scores. Functional outcome was defined as good (GBS disability score 0 to 2) or poor (GBS disability score 3 to 6) at 28 days after admission. The cohort included 22 women and 38 men with a mean age of 50 ± 18 years. In univariate logistic regression analysis, potential factors associated with poor outcome include an older age (P = 0.101), the absence of preceding respiratory tract infection (P = 0.043), mechanical ventilation (P = 0.016), a lower hematocrit (p = 0.072), a lower serum sodium level (P = 0.153) and a higher disability score on admission (P < 0.001). In multivariate analysis, a higher disability score on admission was associated with a poorer outcome (OR, 5.61; 95% CI, 2.34 to 13.43; P < 0.001), whereas the presence of prodromal upper respiratory tract infection correlated with a better outcome (OR, 0.13; 95% CI, 0.03-0.59; P = 0.009). Among 60 patients, eleven (18.3%) have various complications attributed to plasmapheresis treatment. Six patients (10.0%) developed deep vein thrombosis and two experienced catheter-related infection (3.3%). Hypotension, allergy and hemolysis occurred in one patient each (1.7%). In conclusion, we describe our experiences of using DFPP in the treatment of GBS. The pretreatment severity score was the most significant predictor of treatment outcome, suggesting that early referral and timely treatment are important. Potential complications such as catheter-related infection and deep vein thrombosis should be monitored carefully.

[1]  M. Kiernan,et al.  Guillain-Barré syndrome: An update , 2009, Journal of Clinical Neuroscience.

[2]  J. Schessl,et al.  Clinical Presentation and Course of Childhood Guillain-Barré Syndrome: A Prospective Multicentre Study , 2007, Neuropediatrics.

[3]  M. Ogino,et al.  Tryptophan‐immobilized Column‐based Immunoadsorption as the Choice Method for Plasmapheresis in Guillain–Barré Syndrome , 2004, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[4]  A. Kaplan Therapeutic plasma exchange: core curriculum 2008. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  Cheng-Hsien Lu,et al.  Long‐term prognosis for Guillain‐Barré syndrome: Evaluation of prognostic factors and clinical experience of automated double filtration plasmapheresis , 2003, Journal of clinical apheresis.

[6]  S. Hsieh,et al.  Plasma exchange versus double filtration plasmapheresis in the treatment of Guillain-Barré syndrome. , 2002, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[7]  D. Cornblath,et al.  Evidence-based guideline update: Plasmapheresis in neurologic disorders , 2011, Neurology.

[8]  M. Mori,et al.  Haemophilus influenzae infection and Guillain-Barré syndrome. , 2000, Brain : a journal of neurology.

[9]  W. Szczeklik,et al.  Complications in patients treated with plasmapheresis in the intensive care unit. , 2013, Anaesthesiology intensive therapy.

[10]  P. Doorn Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS) , 2013 .

[11]  R. Hughes,et al.  CONTROLLED TRIAL OF PREDNISOLONE IN ACUTE POLYNEUROPATHY , 1978, The Lancet.

[12]  D. Kiprov,et al.  Adverse reactions associated with mobile therapeutic apheresis:Analysis of 17,940 procedures , 2001, Journal of clinical apheresis.

[13]  S. Vesely,et al.  Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura‐hemolytic‐uremic syndrome , 2000 .

[14]  W. Hacke,et al.  Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome , 1997 .

[15]  K. Hirata,et al.  Ability to remove immunoglobulins and anti-ganglioside antibodies by plasma exchange, double-filtration plasmapheresis and immunoadsorption , 1998, Journal of the Neurological Sciences.

[16]  B. Colls Guillain−Barré syndrome and hyponatraemia , 2003, Internal medicine journal.

[17]  R. Weinstein,et al.  Complications of therapeutic plasma exchange: A recent assessment , 1994, Journal of clinical apheresis.

[18]  P. Schmitz,et al.  A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. , 1992, The New England journal of medicine.

[19]  H. Hartung,et al.  Preceding infections, immune factors, and outcome in Guillain–Barré syndrome , 2001, Neurology.

[20]  R. Weinstein,et al.  Guidelines on the use of therapeutic apheresis in clinical practice—Evidence‐based approach from the apheresis applications committee of the American society for apheresis , 2007, Journal of clinical apheresis.

[21]  V. Bril,et al.  Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barre syndrome , 1996, Neurology.

[22]  M. Musthafa,et al.  Guillain-Barré syndrome and SIADH , 2011, Neurology.

[23]  M. Versino,et al.  Guillain-Barré syndrome , 2006, Neurological Sciences.

[24]  D. Annane,et al.  Immunotherapy for Guillain-Barré syndrome: a systematic review. , 2007, Brain : a journal of neurology.

[25]  B. Jacobs,et al.  Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome , 2008, The Lancet Neurology.

[26]  A. Soysal,et al.  Clinico‐electrophysiological findings and prognosis of Guillain‐Barré syndrome – 10 years’ experience , 2011, Acta neurologica Scandinavica.

[27]  A. Pithadia,et al.  Guillain-Barré syndrome (GBS) , 2010, Pharmacological reports : PR.

[28]  H. Chiu,et al.  Experience of double filtration plasmapheresis in the treatment of Guillain‐Barré syndrome , 1999, Journal of clinical apheresis.

[29]  E. Steyerberg,et al.  A clinical prognostic scoring system for Guillain-Barré syndrome , 2007, The Lancet Neurology.

[30]  A. Uncini,et al.  Outcome and its predictors in Guillain–Barré syndrome , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[31]  Hester F. Lingsma,et al.  Early recognition of poor prognosis in Guillain-Barré syndrome , 2011, Neurology.

[32]  C.-H. Lu,et al.  Guillain–Barré syndrome in southern Taiwan: clinical features, prognostic factors and therapeutic outcomes , 2003, European journal of neurology.

[33]  A. Chiò,et al.  Guillain-Barré syndrome , 2003, Neurology.

[34]  O. Gungor,et al.  Plasmapheresis therapy in renal transplant patients: five-year experience. , 2011, Transplantation proceedings.

[35]  R. Porcher,et al.  Clinical and electrophysiological predictors of respiratory failure in Guillain-Barré syndrome: a prospective study , 2006, The Lancet Neurology.

[36]  J. Arpa,et al.  Guillain-Barré Syndrome: Natural history and prognostic factors: a retrospective review of 106 cases , 2013, BMC Neurology.

[37]  L. Hickson,et al.  Severe Hyponatremia as the Initial Sign Preceding Guillain-Barré Syndrome, an Acute Inflammatory Demyelinating Polyneuropathy: A Case Report , 2013, Case reports in neurological medicine.

[38]  A. Kaplan,et al.  Therapeutic plasma exchange: complications and management. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.